Compare LAW & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAW | ENTA |
|---|---|---|
| Founded | 2013 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.2M | 486.3M |
| IPO Year | 2021 | 2012 |
| Metric | LAW | ENTA |
|---|---|---|
| Price | $4.76 | $13.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $8.00 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 656.3K | 184.0K |
| Earning Date | 05-25-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.58 | ★ 29.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $156,849,000.00 | $102,814,000.00 |
| Revenue This Year | $11.23 | $5.91 |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.29 | ★ 16.48 |
| 52 Week Low | $2.45 | $4.09 |
| 52 Week High | $9.11 | $17.15 |
| Indicator | LAW | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.81 | 44.83 |
| Support Level | $3.92 | $13.39 |
| Resistance Level | $5.10 | $13.98 |
| Average True Range (ATR) | 0.45 | 0.86 |
| MACD | 0.30 | -0.03 |
| Stochastic Oscillator | 91.17 | 15.79 |
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.